Zoster Ophthalmicus Ocular Pain

What is Zoster ophthalmicus ocular pain?

Zoster ophthalmicus (also called herpes zoster ophthalmicus, HZO) is a re‑activation of the varicella‑zoster virus (VZV) that involves the ophthalmic branch (V1) of the trigeminal nerve. When the virus spreads to the eye and surrounding structures, patients often experience a sharp, burning, or throbbing ocular pain that may precede the classic skin rash.

The pain is caused by inflammation of the sensory nerves that innervate the cornea, conjunctiva, eyelids, and surrounding skin. Because the ophthalmic branch supplies the cornea—a highly innervated structure—pain can be severe and may be accompanied by light sensitivity (photophobia), tearing, and a gritty sensation.

Prompt recognition is essential, because untreated HZO can lead to serious eye complications, including vision loss.

Common Causes

While the primary cause of Zoster ophthalmicus ocular pain is VZV reactivation, several conditions can predispose a person to develop HZO or mimic its pain. Below are 8‑10 common contributors:

• Varicella‑zoster virus reactivation – the direct cause of HZO.
• Advanced age – immune function declines after 50 years, increasing risk.
• Immunosuppression – HIV/AIDS, organ transplantation, chemotherapy, or high‑dose steroids.
• Chronic medical conditions – diabetes, chronic kidney disease, and malignancy.
• Previous chickenpox infection – everyone who had chickenpox carries latent VZV.
• Stress or trauma – physical or emotional stress can trigger viral reactivation.
• Severe ocular surface disease – dry eye or prior corneal injury may worsen pain when HZO occurs.
• Other viral eye infections – herpes simplex virus (HSV) keratitis can produce similar pain patterns.
• Neuropathic pain disorders – conditions like trigeminal neuralgia can be confused with HZO pain.
• Allergic or bacterial conjunctivitis – while not a cause, they may coexist and amplify discomfort.

Associated Symptoms

Ocular pain in HZO rarely occurs in isolation. The following symptoms are frequently reported and can help differentiate it from other eye conditions:

• Dermatomal rash – vesicular lesions on the forehead, scalp, or nose (Hutchinson’s sign).
• Redness (conjunctival injection) – may be diffuse or sectoral.
• Photophobia – intolerance to bright light.
• Tearing (epiphora) – excessive watery discharge.
• Blurred vision – due to corneal involvement, uveitis, or edema.
• Foreign‑body sensation – gritty feeling often described as “sand in the eye.”
• Eye swelling – eyelid edema or ptosis.
• Headache – may radiate from the temple to the forehead.
• Fever or malaise – systemic signs of viral infection.

When to See a Doctor

Because HZO can threaten vision, early medical evaluation is crucial. Seek professional care promptly if you notice any of the following:

• Sudden onset of eye pain with or without a rash on the forehead, scalp, or nose.
• Redness, swelling, or discharge from the eye that does not improve within 24 hours.
• Blurred vision, double vision, or loss of vision.
• Severe photophobia that limits daily activities.
• Fever, chills, or feeling generally unwell.
• History of immune compromise (e.g., chemotherapy, HIV, steroids).

If you have any doubts, err on the side of caution and contact an ophthalmologist or go to an urgent‑care clinic.

Diagnosis

An accurate diagnosis relies on a combination of clinical examination and, when needed, ancillary testing.

Clinical Evaluation

1. History taking – onset of pain, presence of rash, prior chickenpox, immune status.
2. Visual acuity test – determines baseline vision.
3. Slit‑lamp examination – allows the clinician to view corneal lesions, conjunctival injection, and any vesicles on the eyelid or conjunctiva.
4. Fundoscopic exam – assesses the retina and optic nerve for inflammation.
5. Neurological assessment – evaluates trigeminal nerve function and looks for Hutchinson’s sign (lesions on the tip of the nose, indicating nasociliary involvement and higher risk of ocular disease).

Laboratory & Imaging (when indicated)

• Polymerase chain reaction (PCR) of vesicular fluid or conjunctival swab to confirm VZV DNA.
• Viral culture – rarely used but may be performed in atypical cases.
• Serology – VZV IgM/IgG can support a recent infection.
• Anterior segment optical coherence tomography (AS‑OCT) – visualizes corneal thickness and edema.
• Ultrasound B‑scan – for posterior segment involvement if vision is rapidly worsening.

Treatment Options

Management of HZO ocular pain focuses on three goals: eliminating viral replication, reducing inflammation, and preserving vision.

Antiviral Therapy (First‑line)

• Acyclovir 800 mg orally five times daily for 7–10 days.
• Valacyclovir 1 g orally three times daily (preferred for better bioavailability).
• Famciclovir 500 mg orally three times daily.
• Intravenous acyclovir may be required for immunocompromised patients or severe ocular involvement.

Antivirals are most effective when started within 72 hours of rash onset, but treatment should still be initiated even later because ocular complications can be prevented.

Corticosteroids

Topical corticosteroid eye drops (e.g., prednisolone acetate 1%) are often added after antivirals are underway to diminish stromal keratitis and uveitis. Systemic steroids may be considered in select cases, but only under ophthalmology supervision due to the risk of exacerbating viral replication.

Pain Management

• Topical anesthetic drops (e.g., proparacaine) – short‑term use for severe acute pain.
• Systemic analgesics – acetaminophen or NSAIDs for mild‑moderate pain.
• Neuropathic pain agents – gabapentin or pregabalin for lingering burning sensation after the rash resolves (post‑herpetic neuralgia).
• Cold compresses – applied to the closed eyelid for brief relief.

Supportive Eye Care

• Lubricating eye drops (preservative‑free artificial tears) – maintain surface moisture.
• Patch or shield – protects the eye from inadvertent trauma, especially if there is corneal ulceration.
• Contact lens avoidance – discontinue use until the cornea is clear.

Follow‑up Care

Patients should be re‑evaluated within 48–72 hours after initiating therapy, then weekly until the epithelium heals. Long‑term follow‑up may be needed for post‑herpetic neuralgia or secondary glaucoma.

Prevention Tips

Because HZO results from reactivation of a dormant virus, complete elimination is impossible, but risk can be reduced.

• Vaccination – The recombinant zoster vaccine (Shingrix) is >90 % effective in preventing shingles and is recommended for adults ≥50 years and immunocompromised adults ≥19 years (CDC).
• Maintain a healthy immune system – balanced diet, regular exercise, adequate sleep, and stress management.
• Control chronic diseases – keep diabetes, hypertension, and HIV well‑controlled.
• Avoid unnecessary steroids – use the lowest effective dose and taper when possible.
• Hand hygiene – reduces the spread of VZV to people who have not had chickenpox.
• Prompt treatment of initial shingles – early antiviral therapy for any dermatome reduces the chance of ophthalmic involvement.

Emergency Warning Signs

Key Take‑aways

Zoster ophthalmicus ocular pain is a potentially sight‑threatening manifestation of shingles that demands swift antiviral treatment and close ophthalmic monitoring. Recognizing the characteristic pain, accompanying rash, and early eye signs can prevent complications such as corneal scarring, glaucoma, and permanent vision loss. Vaccination, good immune health, and early therapy are the best preventive strategies.

---

References:

1. Mayo Clinic. “Shingles (Herpes Zoster).” https://www.mayoclinic.org (accessed April 2026).
2. CDC. “Shingles (Herpes Zoster) – Prevention.” https://www.cdc.gov (accessed April 2026).
3. National Institute of Allergy and Infectious Diseases (NIH). “Herpes Zoster Ophthalmicus.” https://www.niaid.nih.gov (accessed April 2026).
4. Cleveland Clinic. “Zoster Ophthalmicus (Shingles Eye Infection).” https://my.clevelandclinic.org (accessed April 2026).
5. World Health Organization. “Shingles Vaccines: Recommendations.” https://www.who.int (accessed April 2026).
6. American Academy of Ophthalmology. “Herpes Zoster Ophthalmicus.” https://www.aao.org (accessed April 2026).